ARTICLE | Clinical News
BMS-986036: Ph II data
April 7, 2017 7:18 PM UTC
A double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 each met the primary en...
BCIQ Target Profiles